Rel/NF-kB transcription factors are key regulators of immune, in¯ammatory and acute phase responses and are also implicated in the control of cell proliferation and apoptosis. Remarkable progress has been made in understanding the signal transduction pathways that lead to the activation of Rel/NF-kB factors and the consequent induction of gene expression. Evidence linking deregulated Rel/NF-kB activity to oncogenesis in mammalian systems has emerged in recent years, consistent with the acute oncogenicity of the viral oncoprotein v-Rel in animal models. Chromosomal ampli®cation, overexpression and rearrangement of genes coding for Rel/NF-kB factors have been noted in many human hematopoietic and solid tumors. Persistent nuclear NF-kB activity was also described in several human cancer cell types, as a result of constitutive activation of upstream signaling kinases or mutations inactivating inhibitory IkB subunits. Studies point to a correlation between the activation of cellular gene expression by Rel/NF-kB factors and their participation in the malignant process. Experiments implicating NFkB in the control of the apoptotic response also support a role in oncogenesis and in the resistance of tumor cells to chemotherapy. This review focuses on the status of the rel, nfkb and ikb genes and their activity in human tumors and their association with the onset or progression of malignancies.
Introduction
The signaling pathways that govern cell proliferation, survival and oncogenesis are of prime interest in cancer biology. Chromosomal aberrations aecting the structure or the expression of genes coding for components of these pathways are often directly implicated in tumor development and progression. Since the discovery of the mammalian Rel/NF-kB factors 13 years ago, research eorts have focused on their transcriptional and biological functions and on the mechanisms that control their activity. The vertebrate members of this family regulate immune, in¯ammatory and acute phase responses and their homozygous inactivation in mice results in severe immune system dysfunction (reviewed in Gerondakis et al., 1999, this issue; Ghosh et al., 1998) .
Vertebrate Rel/NF-kB transcription factors include RelA, RelB, c-Rel, p50/p105 and p52/p100 (Chen and Ghosh, 1999, this issue) . These proteins are structurally-related through an approximately 300 amino acid (aa) N-terminal domain called the Rel homology (RH) domain, which contains sequences important for DNA binding, dimerization and inhibitor (IkB) binding. The C-terminal halves of RelA, RelB and c-Rel contain transcriptional activation domains, whereas the Cterminal halves of p105 and p100 contain inhibitory domains. The mature DNA-binding forms of p105 and p100 are shortened forms called p50 and p52, respectively. Nearly all Rel/NF-kB proteins can form homodimers and heterodimers, which bind to DNA target sites (kB sites) to in¯uence gene expression. The most common dimer is a p50-RelA heterodimer, speci®cally called NF-kB. In most normal cells, these Rel/NF-kB dimers are retained in the cytoplasm as an inactive complex through the direct binding of an IkB inhibitor. Various signals, including many cytokines, can lead to degradation of the IkB protein and the resultant translocation of the active Rel/NF-kB complex into the nucleus (Pahl, 1999; Karin, 1999, both this issue) .
Rel/NF-kB proteins also participate in cellular growth control and neoplasia (reviewed also in Gilmore et al., 1999) . The viral oncoprotein v-Rel was the ®rst member of this family to be identi®ed and is still the only one that is acutely transforming in vitro and in vivo (Gilmore, 1999, this issue) . Several oncogenic viruses, such as human T-cell leukemia virus type I (HTLV-1) and Epstein-Barr virus (EBV), activate NF-kB as part of the transformation process (Cahir McFarland et al., 1999; Sun and Ballard, 1999 ; both this issue). Moreover, there is growing evidence implicating all vertebrate Rel/NF-kB factors in human tumors, with the notable exception of RelB. Chromosomal aberrations involving the human c-rel, rela, nfkb1 and nfkb2 genes are found in many hematopoietic and solid tumors. Alterations aecting the expression or function of the IkB family members Bcl-3, IkBa and IkBe have also been observed in several cancers. The last few years have seen a virtual explosion in the identi®cation of tumor cells that display constitutively high levels of nuclear NF-kB activity due to hyperactivation of the NF-kB signaling pathway or to inactivating mutations in the regulatory IkB subunits. These important ®ndings warrant further analysis of the role of Rel/NF-kB factors in human malignancies.
c-rel gene ampli®cation and rearrangement in leukemias and lymphomas c-rel encodes a potent transcriptional activator of genes that display kB DNA sites in their enhancer regions. Mice with homozygous mutations in the c-rel locus show severely impaired lymphocyte proliferation and immune function (Carrasco et al., 1998; Gerondakis et al., 1999, this issue; KoÈ ntgen et al., 1995; Tumang et al., 1998) . The implication of c-rel in neoplasia was initially suggested by the acute oncogenicity of its viral derivative, the v-Rel oncoprotein (Gilmore, 1999, this issue) , which induces aggressive leukemias/lymphomas in chickens and transgenic mice. Moreover, elevated crel gene expression was reported in a chicken B-cell lymphoma containing a proviral insertion in the c-rel promoter (Kabrun et al., 1990) . Overexpression of c-rel transforms primary chicken lymphoid cells and embryo ®broblasts, albeit at a much lower frequency than v-rel, and occasionally gives rise to lymphoid tumors in young chickens (Abbadie et al., 1993; HrdlickovaÂ et al., 1994; Kralova et al., 1994; Nehyba et al., 1994) . The demonstration that v-rel is also oncogenic in transgenic mice (Carrasco et al., 1996) generated great interest in the search for aberrant c-rel gene expression and/or activity in human tumors.
Ampli®cation of the human c-rel gene (to 54 copies) on chromosome 2p14-15 (Brownell et al., 1988; Mathew et al., 1993) was observed in 23% of diuse lymphomas with a large cell component (DLLC), which constitute approximately 50% of Bcell non-Hodgkin's lymphomas (Table 1 ; Barth et al., 1998; Houldsworth et al., 1996; Rao et al., 1998) . Ampli®cation of the c-rel locus was also noted in primary mediastinal (thymic) B-cell lymphomas and in certain follicular large cell lymphomas (Table 1; Houldsworth et al., 1996; Joos et al., 1996; Lu et al., 1991; Rao et al., 1998) . c-rel gene ampli®cation is also associated with extranodal presentation in 75 ± 85% of DLLCs, establishing it as one of the most frequent genetic alterations in DLLC (Houldsworth et al., 1996; Rao et al., 1998) .
Although it is still unclear whether c-rel gene ampli®cation initiates the transformation process or drives tumor progression, it is often associated with advanced stage disease (Barth et al., 1998; Houldsworth et al., 1996; Rao et al., 1998) . That c-rel ampli®cation is frequently accompanied by other chromosomal alterations characteristic of tumor progression suggests that it is a progression-associated marker of primary extranodal lymphomas (Houldsworth et al., 1996; Rao et al., 1998) . The observation that duplications of chromosome 2p are associated with poor prognosis in certain large cell lymphomas supports this model (Yunis et al., 1989) . To date, there is no evidence that structural alterations occur in ampli®ed c-rel genes in human tumors; however, the presence of subtle mutations that promote its oncogenicity has not been ruled out. Research eorts are currently focused on the role of c-rel gene ampli®cation in lymphomagenesis (RSK Chaganti, personal communication). Deregulated gene expression as a consequence of c-rel overexpression is a likely outcome.
Although it is most commonly ampli®ed in human lymphomas, the c-rel gene has also been shown to have undergone rearrangement in a few follicular lymphomas and in some DLLCs (Table 1; Lu et al., 1991) . A chromosomal rearrangement that created a hybrid protein (called c-Rel-Nrg) comprised of the Nterminal RH domain of c-Rel fused to unrelated gene sequences was observed in a human diuse lymphoma cell line (Lu et al., 1991) . The resulting deletion of the C-terminal c-Rel transactivation domain is reminiscent of the c-rel gene recombinant that gave rise to the v-rel oncogene (Gilmore, 1999, this issue) . It is also similar to the recovery of C-terminally truncated c-Rel proteins from rare cases of c-rel-induced tumors in chickens . Interestingly, knockout mice with a homozygous deletion of the C-terminal Rel/NF-kB/IkB factors in oncogenesis B Rayet and C Ge Â linas transactivation domain of c-Rel develop lymphoid cell hyperplasia (Carrasco et al., 1998) . Together, these ®ndings are consistent with a model in which the loss of the C-terminal transactivation domain of c-Rel may provide a selective growth advantage. c-Rel and other NF-kB factors have been shown to induce growth arrest or display a pro-apoptotic phenotype when expressed at high levels in some systems (Abbadie et al., 1993; Bash et al., 1997; Grimm et al., 1996; Huguet et al., 1997; Seitz et al., 1998; Sheehy and Schlissel, 1999; Zurovec et al., 1998) . These ®ndings suggest that structural alterations in c-rel may be necessary in some cases for the manifestation of its oncogenic properties. In other instances, cytogenetic abnormalities aecting other genes may counterbalance these eects.
c-rel overexpression in non-small cell lung carcinoma While c-rel has mostly been implicated in lymphoid tumors, a small scale analysis of human non-small cell lung carcinomas (NSCLC) revealed elevated c-rel expression in 50% of cases analysed (Table 2 ; Mukhopadhyay et al., 1995) . Thus, the association of c-rel with human cancers may not be limited to lymphoid cells and a comprehensive analysis of c-rel in solid tumors may be particularly informative.
rela gene alterations in leukemias and lymphomas
The human rela gene encodes the 65 kDa subunit of NF-kB and maps to chromosome 11q13 (Mathew et al., 1993) . Like c-Rel, RelA exhibits strong transcriptional activity. Unlike c-rel, however, chromosomal aberrations involving rela are only infrequently found in human lymphoid tumors. There have been sporadic reports of rela gene translocation in nonHodgkin's lymphomas and multiple myelomas, and ampli®cation was observed in a few cases of DLLC (Table 1; Houldsworth et al., 1996; Lai et al., 1995; Van den Berghe et al., 1979) . In one multiple myeloma, rela contains a point mutation in its transactivation domain that reduces its transactivation potential (Table 1; Trecca et al., 1997) . Despite these examples, an extensive survey of non-Hodgkin's lymphomas, multiple myelomas, B-cell chronic lymphocytic leukemias, B-and T-cell acute lymphocytic leukemias and cutaneous T-cell lymphomas (CTCL) showed neither ampli®cation nor obvious rearrangement of the rela locus . The RelA protein interacts with factors critical for cellular gene expression and cell cycle progression (Perkins et al., 1997; Schmitz et al., 1995; Xu et al., 1993; Zhong et al., 1998) and its inactivation in mice results in massive liver cell apoptosis (Beg et al., 1995b) . Consequently, many alterations in rela that impair cell growth or survival may be incompatible with cellular transformation. As described in detail below, this hypothesis is consistent with the observation that the persistent activation of NF-kB complexes containing RelA in dierent tumor cell types is necessary for cell growth, survival and tumorigenicity.
rela gene ampli®cation, overexpression and variants in human carcinomas
The participation of rela in solid tumors is a subject of debate. Studies using antisense oligonucleotides to inhibit rela expression in transformed cell lines ®rst suggested a role for rela in neoplastic transformation. While these studies reported reduced cell growth and adhesion and tumor regression (Higgins et al., 1993; Kitajima et al., 1992) , subsequent work disputed the speci®city of these eects (Khaled et al., 1996) . rela gene ampli®cation has been noted in squamous carcinomas of head and neck, and in adenocarcinomas of breast and stomach (Table 2 ; Mathew et al., 1993; Motokura and Arnold, 1993 ). An increase in rela expression was reported in thyroid carcinoma cell lines (Visconti et al., 1997) . In this instance antisense rela oligomers greatly reduced cell growth and colony formation in agar, whereas inhibition of p50 had no eect. A rela splice variant was identi®ed in nonsmall cell lung carcinoma . A second splice variant was reported to transform ®broblasts in culture (Narayanan et al., 1992) , but others failed to detect this activity (Grimm and Baeuerle, 1994) . Thus, a de®nitive correlation between altered rela gene expression and human carcinomas remains to be established. The nfkb1 gene encodes the p50/p105 subunit of NFkB and is found on human chromosome 4q24 (Mathew et al., 1993) . Despite its ubiquitous participation in NF-kB-mediated gene activation in the immune system, few alterations in the structure and expression of nfkb1 have been reported in leukemias and lymphomas. This is reminiscent of the situation with rela. Given the prevalent participation of RelA and p50 in NF-kB-mediated transcription, it is tempting to speculate that structural changes in these proteins may adversely aect the growth or survival of tumor cells. However, there are some examples of nfkb1 gene rearrangement in certain acute lymphoblastic leukemias (Table 1; Liptay et al., 1992) . Of potential interest, p105 was recently shown to associate with LYL1, a bHLH protein involved in a translocation in certain human T-cell acute leukemias (T-ALL; Ferrier et al., 1999) . Ectopic expression of LYL1 in T cells alters the ratio of p105 to the mature p50 protein, resulting in the repression of NF-kB-dependent gene activation by p50-p50 homodimers. The signi®cant homology between LYL1 and TAL-1 may also be relevant, as TAL-1 activation is associated with a large number of human T-ALLs. Further work is needed to assess the frequency of nfkb1 gene alterations in human leukemias and lymphomas, and to evaluate the physiological signi®cance of p105 interaction with LYL1 for oncogenesis.
Overexpression of nfkb1 in human carcinomas
Signi®cant overexpression of the p50 subunit of NFkB was encountered in cell lines derived from nonsmall cell lung carcinomas (NSCLC) and in 80% of NSCLC cases examined (Table 2 ; Bours et al., 1994; Mukhopadhyay et al., 1995) . Elevated levels of p50 were also noticed in transformed cells from colon, prostate, breast, bone and brain (Table 2 ; Mukhopadhyay et al., 1995) . The inappropriate expression of p50 in these tumors is likely to contribute to the malignant process by forming heterodimers with other Rel/NF-kB factors.
nfkb2 gene rearrangements in human lymphomas
Unlike its relative nfkb1, chromosomal translocations and deletions aecting the nfkb2 locus on human chromosome 10q24 (Mathew et al., 1993) are found in many lymphomas . In fact, nfkb2 was the ®rst member of the rel gene family to be found rearranged in human tumors. nfkb2 gene rearrangements are present in a small percentage of B-cell non-Hodgkin lymphomas, chronic lymphocytic leukemias, and multiple myelomas, and are frequently observed in cutaneous T-cell lymphomas and are associated with poor prognosis (CTCL; Table 1 ; Chang et al. in preparation; Fracchiolla et al., 1993; Migliazza et al., 1994; Neri et al., 1991 Neri et al., , 1995 Thakur et al., 1994) .
Chromosomal translocations or deletions in the nfkb2 locus invariably target the 3' coding region of the gene. This results in the production of truncated p100 proteins with a partially deleted C-terminal ankyrin domain that is fused in some cases to heterologous sequences (Fracchiolla et al., 1993; Migliazza et al., 1994; Neri et al., 1991; Thakur et al., 1994; Zhang et al., 1994) . The functional consequence of these rearrangements is the constitutive nuclear localization of tumor-derived truncated p100 proteins, and their binding to kB DNA motifs without further processing to a mature p52 form (Chang et al., 1995; Migliazza et al., 1994; Neri et al., 1991; Thakur et al., 1994; Zhang et al., 1994) . Alterations in tumor-derived p100 proteins commonly result in a loss of the transcriptional repression activity that is typical of wild-type p52 (Bours et al., 1992; Chang et al., 1994; AB Rabson, personal communication) .
Homozygous inactivation of the entire coding sequence of nfkb2 is not tumorigenic (CaamanÄ o et al., 1998; Franzoso et al., 1998) . This argues that the simple loss of the IkB function of p100 is not sucient to account for the oncogenicity of tumorassociated, truncated p100 proteins. Interestingly however, mice carrying a homozygous deletion of the C-terminal ankyrin repeats of p100 but that still express a functional p52 protein display gastric and lymph node hyperplasia (Ishikawa et al., 1997) . These data support a model in which tumor-derived p100 proteins function by altering NF-kB-mediated transcription. Consistent with this prediction, some truncated p100 proteins activate gene expression on their own, suggesting that tumor-derived NF-kB2 proteins may act as constitutive transactivators (Chang et al., 1995; . Other tumor-derived p100 proteins fail to transactivate gene expression by themselves, but synergistically activate transcription with RelA (Guerrini and Blasi, submitted; AB Rabson, personal communication.). Overall, these results highlight the altered transcriptional activity of tumor-derived p100 proteins.
CTCL-derived nfkb2 alleles were reported to transform mouse ®broblasts in vitro and these cells gave rise to tumors in immunode®cient mice (Ciana et al., 1997) . More recently, truncated and fusion p100 proteins derived from a B-cell chronic lymphocytic leukemia and a CTCL specimen were characterized for their eects on cell proliferation and growth in soft agar (Guerrini and Blasi, submitted). A truncated form of p100 synergistically activated transcription with RelA and promoted colony formation in soft agar. Whereas a truncated p100 protein containing a heterologous fusion sequence failed to synergize with RelA and presented a cloning eciency similar to that observed with wild-type p52. The dierent properties of these tumor-derived p100 proteins suggest that they may function through dierent mechanisms to alter kB sitedependent transcription. Direct proof that tumorderived nfkb2 alleles play a role in lymphomagenesis awaits their expression in the lymphoid lineages of transgenic mice. In that no nfkb2 alterations have been detected in early stage mycosis fungoides, nfkb2 gene rearrangements may be a secondary event in CTCL (Chang et al. in preparation) .
PSD is a novel gene located on human chromosome 10q24 adjacent to the 3' end of nfkb2, and PSD is deleted or translocated in rearrangements involving nfkb2 in lymphoid tumors (Perletti et al., 1997) . Although the function of the PSD protein is still unknown, the presence of pleckstrin and Sec7-homology domains indicates a possible role in signal transduction. However, the restricted expression of PSD to brain tissues suggests that its deletion is unlikely to play a role in lymphomas associated with nfkb2 gene alterations.
nfkb2 overexpression in breast and colon carcinomas nfkb2 overexpression was reported in breast and colon carcinomas (Table 2 ; Bours et al., 1994; Dejardin et al., 1995) . In breast cancer cells, this results in very high levels of p100 and p52 proteins (Dejardin et al., 1995; . While p100-expressing breast cancer cells show reduced nuclear NF-kB induction (Dejardin et al., 1999) , other studies revealed high levels of constitutive NF-kB activity in many breast cancer cells (Nakshatri et al., 1997; Sovak et al., 1997; Kim et al. submitted) . Further experiments are therefore needed to evaluate the role of p100 in breast carcinomas.
bcl-3 gene rearrangement and ampli®cation in leukemias and lymphomas
The Bcl-3 protein is structurally related to the IkB family of Rel/NF-kB regulators. However, unlike other IkB molecules, Bcl-3 is found in the nucleus of most cells where it interacts with homodimers of p50 and p52 to alter their DNA-binding activities and modulate gene expression (reviewed in Lenardo and Siebenlist, 1994) . Bcl-3 facilitates NF-kB-mediated transcription by removing inactive p50 homodimers from DNA, and acts as a potent coactivator for homodimers of p52. Interactions of Bcl-3 with the Jab1, Pirin, Tip60 and Bard1 nuclear proteins were recently proposed to link NF-kB to other transcriptional regulators and chromatin remodeling co-factors (Dechend et al., 1999) . Whereas Jab1 enhanced DNA binding by Bcl-3/(p50) 2 complexes, the Tip60 histone acetylase stimulated Bcl-3-mediated kB site-dependent transcription.
The human bcl-3 gene is located on chromosome 19q13.1 and is involved in a rare but recurrent t(14;19)(q32.3;q13.2) translocation in B-cell chronic lymphocytic leukemia (CLL; Table 1 ; Ohno et al., 1990) . This translocation is rarely the only cytogenetic aberration observed in CLL patients, but it is associated with poor prognosis (McKeithan et al., 1987; Michaux et al., 1996 Michaux et al., , 1997 . Translocations aecting bcl-3 in leukemias and lymphomas always result in overexpression of an intact Bcl-3 protein (Table 1; Michaux et al., 1996; Ohno et al., 1990 Ohno et al., , 1993 . Thus, chromosomal translocations involving bcl-3 may very well alter NFkB-dependent gene expression. bcl-3-de®cient mice display a partial loss of B cells, suggesting the participation of Bcl-3 in B-cell survival that may be relevant to its oncogenic activity (Franzoso et al., 1997) . While constitutive expression of bcl-3 in thymocytes failed to induce tumors in mice (CaamanÄ o et al., 1996) , Em-bcl-3 transgenic animals develop a lymphoproliferative disorder characterized by the accumulation of mature B cells (Ong et al., 1998) . This phenotype is consistent with the notion that overexpression of Bcl-3 is a critical step in the multi-step process necessary for leukemogenesis. The Em-bcl-3 transgenic model may thus be useful to study the contribution of other genetic alterations needed for the manifestation of B-cell malignancies associated with overexpression of Bcl-3.
Inactivation of IkB in oncogenesis
IkBa is an important inhibitor of NF-kB (Karin, 1999, this issue) . Studies showing that overexpression of antisense ikba transcripts transformed mouse NIH3T3 cells were the ®rst to propose a role for the inactivation of IkB factors in oncogenesis (Beauparlant et al., 1994) . The neonatal lethality resulting from the homozygous inactivation of ikba in mice has prevented the detection of a potential tumorigenic eect (Beg et al., 1995a; Klement et al., 1996) . The ®nding that ikba7/7 ®broblasts are not transformed raised questions regarding the role of IkBa in cell transformation (Beg et al., 1995a; Klement et al., 1996) . Nonetheless, recent analyses of many human tumors that show persistent nuclear NF-kB DNA binding and transactivation activity have often revealed defective IkB activity. As described below, work on Hodgkin's lymphomas unveiled inactivating mutations in ikba and ikbe (Tables 1 and 3 ; Cabannes and Hay, submitted; Cabannes et al., 1999; Krappmann et al., 1999; Wood et al., 1998) . In other instances, oncogenesis was inversely correlated with the levels of IkBa and IkBb proteins and coincided with the activation of IkB kinases (IKK) that govern the destruction of IkB factors (for example, see Devalaraja et al., 1999; Kordes et al. submitted; Krappmann et al., 1999; Newton et al., 1999) . These results are consistent with the fundamental role of IkB molecules in the regulation of Rel/NF-kB function. In this context, IkBa has been proposed to act as a tumor suppressor to control the oncogenic activation of NF-kB (Cabannes et al., 1999) .
The human ikba gene is located on chromosome 14q13 (Le Beau et al., 1992) . Although this locus is not frequently involved in chromosomal rearrangements or deletions in Hodgkin's disease (Koduru et al., 1993) , it is too early to rule out the possibility that subtle mutations may be involved in many cases. Further work will help to determine if ikb genes are frequently mutated in hematopoietic and solid tumors, or whether deregulation of IKK activity is the preferred mode for NF-kB activation in human cancers.
Constitutive nuclear NF-kB activity in leukemias and lymphomas
Many human leukemias and lymphomas show constitutively active NF-kB in the nucleus. Deregulated NF-kB activation was initially reported in Hodgkin's disease (HD), a lymphoma characterized by the presence of mononuclear Hodgkin (H) cells and multinucleated Reed-Sternberg (RS) cells (Table 3 ; Bargou et al., 1996) . This persistent NF-kB activity is critical for H-RS cell proliferation, resistance to apoptosis and tumor formation when these cells are placed in severe combined immunode®cient (SCID) mice (Bargou et al., 1997) . This suggests an important role for NF-kB in the pathogenesis of HD. In some HD cell lines and in biopsies from patients with relapsed HD, constitutive NF-kB activation appears to be a direct consequence of mutations in the gene encoding IkBa. These mutations invariably produce non-functional IkBa proteins, missing various portions of the central ankyrin domain and C-terminal region (Cabannes et al., 1999; Krappmann et al., 1999; Wood et al., 1998) . Although IkBa seems to be the most frequent target of mutations in HD cells, a mutant allele of IkBe was recently detected in an HD-derived cell line that also contains a mutation in the ikba gene (Table 3 ; Cabannes and Hay, submitted) .
It is important to note that mutations aecting ikb genes are not the only means by which constitutive NF-kB activity is achieved in HD. For instance, activated NF-kB complexes in several other H-RS cell lines result from persistent activation of the signal transduction pathway that leads to the proteolysis of IkBa (Table 3 ; Krappmann et al., 1999) . Indeed, the instability of IkBa in these cells correlated with constitutive IkB kinase activity. That deregulated NFkB activity detected in all HD cases examined is still susceptible to inhibition by recombinant IkBa molecules has important implications for therapy.
Persistent nuclear NF-kB activity is now also being recognized as a common characteristic of childhood acute lymphoblastic leukemia (C-ALL), as activated NF-kB complexes were detected in 93% of cases examined (Table 3 ; Kordes et al. submitted). Inhibition of the proteasome in primary ALL cultures resulted in hyperphosphorylated forms of IkBa. Similar to the scenario described above for HD, these results point to the constitutive activation of upstream IKK kinases and suggest a crucial role for NF-kB in leukemia cell survival.
NF-kB is necessary for bone marrow cell transformation and tumorigenesis by Bcr-Abl, a chimeric oncoprotein involved in acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (Table 3; CML; Reuther et al., 1998) . Bcr-Abl expression leads to increased nuclear translocation of NF-kB and enhances the transactivation function of RelA. This eect is dependent on the tyrosine kinase activity of Bcr-Abl and also partially requires Ras function. However, the exact role of NF-kB in Bcr-Abl-induced leukemias remains to be clari®ed, as the anti-apoptotic activity of NF-kB is not necessary for Bcr-Ablmediated cell survival (Reuther et al., 1998) .
There is ample evidence indicating that the Tax protein of human T-cell leukemia virus type I (HTLV-I) leads to persistent NF-kB activity through the activation of IKK kinases (Sun and Ballard, 1999, this issue) . However, continuous NF-kB activation in primary adult T-cell leukemia (ATL) cells was recently described to also occur through a mechanism that is independent of HTLV-I Tax and that likely involves increased degradation of IkBa (Mori et al., 1999) . Despite the lack of any Tax protein expression in TLOm1 cells, persistent nuclear expression of NF-kB DNA-binding complexes comprised of RelA/p50 was observed (Mori et al., 1999) . These complexes are distinct from the major c-Rel/p50 DNA-binding complexes found in HTLV-1-infected T cells that constitutively express Tax. Thus, it appears that dierent NF-kB subunit activation can occur in primary leukemic cells derived from ATL patients that do not express signi®cant levels of Tax (Mori et al., 1999) . The contribution of these complexes to leukemogenesis has yet to be addressed.
Persistent nuclear NF-kB activity in solid tumors
Continuous activation of NF-kB factors is also emerging as a hallmark of various types of solid tumors, including breast (Table 3 ; Dejardin et al., 1999; Nakshatri et al., 1997; Sovak et al., 1997) , ovarian (Bours et al., 1994; Dejardin et al., 1999) , colon (Dejardin et al., 1999) , pancreatic (Wang et al., 1999b) , thyroid (Visconti et al., 1997) , bladder (Sumitomo et al., 1999b) and prostate carcinomas (Herrmann et al., 1997; Sumitomo et al., 1999a; Payvandi et al. submitted) , as well as in melanomas (Devalaraja et al., 1999) . As with Hodgkin's disease, NF-kB activity is generally associated with the growth and survival of the tumor cells. Elevated NF-kB activity was attributed to defective IkBa function, consistent with the scenario observed in NF-kBassociated leukemias/lymphomas (Table 3) . Given the prevalence of breast and prostate cancers, their association with misregulated NF-kB activity is reviewed in greater detail below.
Many breast cancer cell lines, most primary human breast cancer specimens and a majority of carcinogeninduced mammary tumors in rats exhibit high levels of nuclear NF-kB DNA-binding activity comprised of RelA, c-Rel and p50 (Nakshatri et al., 1997; Sovak et al., 1997) , although others have observed substantial (Dejardin et al., 1999) . Notably, the activation of NF-kB appears to be an early event that occurs prior to the malignant transformation of human mammary epithelial cells in vitro and in rats treated with carcinogen in vivo (Kim et al., submitted). These ®ndings support a model in which NF-kB may be involved early in the progression of breast epithelial cells towards malignancy and may have important implications for early diagnosis. One group reported that NF-kB activation correlates with the conversion of breast cancer cells to hormoneindependent growth, a characteristic of more aggressive and metastatic tumors (Nakshatri et al., 1997) . However, others did not see this correlation (Dejardin et al., 1999) . Experiments are underway to directly assess the role of enhanced NF-kB activity in breast cell neoplasia by expressing NF-kB subunits in the mammary gland of transgenic mice (Kim et al. submitted) .
Primary prostate cancer tissue and prostate cancer cell lines also show constitutive NF-kB activity that is necessary for cell resistance to apoptosis (Herrmann et al., 1997; Payvandi et al. submitted; Sumitomo et al., 1999a) . The inhibition of NF-kB also decreased prostate cancer cell growth in vitro and led to a marked reduction in the incidence and growth of tumors in nude mice (Payvandi et al. submitted). As with other tumors, these results suggest an important role for NF-kB in the onset of prostate cancer or in its progression to invasion and metastasis.
Many human tumors frequently contain mutations in ras genes. Interestingly, NF-kB is a critical downstream mediator of cell transformation mediated by oncogenic ras (Table 3; Finco et al., 1997; Mayo et al., 1997) . In this context, the transcriptional activity of RelA is signi®cantly increased in Ras-transformed cells as compared to non-transformed cells (Finco et al., 1997) . It is thus reasonable to expect that activation of the Ras pathway in human tumors may yet be another means to induce constitutive NF-kB activity and oncogenesis. In agreement with this hypothesis, RelA has been observed to be constitutively activated in 67% of pancreatic adenocarcinomas and the human K-ras oncogene is frequently mutated in pancreatic cancer (Wang et al., 1999b) . Further experiments are nevertheless needed to formally address this model, as preliminary data indicate that oncogenic ras transformation of 3T3 cells derived from rela7/7 mice is normal (AA Beg, personal communication).
Implication of Rel/NF-kB in cell survival, proliferation and immune surveillance: perspective for therapy There is much evidence that cellular Rel/NF-kB activity can protect normal cells from stimuli-induced apoptosis (Barkett and Gilmore, 1999, this issue) . In addition, the anti-apoptotic activity of the v-Rel oncoprotein is essential for its oncogenic function White et al., 1995; Zong et al., 1997) . Therefore, inappropriate NF-kB activity may contribute to the onset or the progression of tumors by promoting cell survival. Consistent with this hypothesis, the functional inactivation of NF-kB in many tumor cell types induces apoptosis and antagonizes oncogenicity (Bargou et al., 1997; Herrmann et al., 1997; Mayo et al., 1997; Sovak et al., 1997; Sumitomo et al., 1999a; Visconti et al., 1997; Payvandi et al. submitted) . NF-kB induces the expression of several apoptosis inhibitors (Barkett and Gilmore, 1999, this issue) , including c-IAP1, c-IAP2, Traf1, Traf2, A20, IEX-1L and the Bcl-2-homologs B¯-1/A1 and Bcl-X (Chen et al., submitted; Chu et al., 1997; Krikos et al., 1992; Lee et al., 1999; Wang et al., 1998 Wu et al., 1998; You et al., 1997; Zong et al., 1999) . However, the role of these factors in tumors that display deregulated NF-kB activity remains to be elucidated.
NF-kB induces the expression of growth factors, cytokines and other factors involved in stress responses, cell proliferation and cell cycle progression (reviewed in Ghosh et al., 1998; Pahl, 1999, this issue; Siebenlist et al., 1994) . Candidate target genes in the latter category include c-myc (Duyao et al., 1990; La Rosa et al., 1994) and cyclin D1 Hinz et al., 1999) . In addition, RelA participates in protein-protein interactions with the cell cycle regulatory complex cyclin E-Cdk2 via its association with CBP/p300 (Perkins et al., 1997) and with the p16 Ink4 cyclindependent kinase inhibitor (Wol and Naumann, 1999) . While NF-kB activity is usually associated with increased cell proliferation, high level expression of cRel or RelA has been reported to result in cell growth arrest at the G1/S phase cell cycle transition in cell culture systems Sheehy and Schlissel, 1999; Zurovec et al., 1998) . Likewise, alterations in NFkB function in transgenic epithelial tissue also demonstrated a growth inhibitory role for NF-kB (Seitz et al., 1998) . Taken together, these results indicate that NF-kB may utilize dierent avenues to control cell division and that a delicate balance in the level of NF-kB activity must be achieved for normal cell proliferation.
In certain systems the upregulation of NF-kB is associated with advanced stages of oncogenesis, supporting a role in tumor progression. In this respect, NF-kB activates the expression of genes important for invasion and metastasis. These include angiogenic factors like VEGF, proteolytic enzymes such as matrix metalloproteinases, urokinase plasminogen activator (uPA) and cell adhesion molecules such as ICAM-1 (Pahl, 1999, this issue) . uPA is signi®cantly increased in most breast cancer cell lines that contain constitutively active NF-kB, it is required for intravasation and is associated with poor prognosis (Newton et al., 1999) . This supports a role for NF-kB in metastasis.
The ability of tumor cells to evade immune surveillance is another contributing factor to tumor progression. Although T lymphocytes in®ltrate solid tumors, the immune response to tumor antigens is compromised in cancer patients. Recent studies indicate that a signi®cant proportion of patients with renal cell carcinoma (RCC) show impaired T-cell signaling as a result of defective NF-kB activation (Uzzo et al., 1999) . Low molecular weight soluble products from RCC explants can inhibit NF-kB in T lymphocytes (Ling et al., 1998) . Thus, reduced NF-kB signaling in immune cells from cancer patients likely contributes to tumor progression.
Because deregulated NF-kB activity in many dierent tumor cell types is still susceptible to inhibition by recombinant IkBa molecules, there is hope for the development of eective approaches to restrict tumor growth, based on the many inhibitors of Rel/NF-kB activity (Epinat and Gilmore, 1999, this issue) . Moreover, the correlation between NF-kB activity and the resistance of cancer cells to chemotherapeutic agents and ionizing radiation oers the possibility to enhance the ecacy of anti-cancer therapies by antagonizing NF-kB activity (Wang et al., 1996) . Indeed, Wang and collaborators recently showed that the delivery of a super-repressor form of IkBa in chemoresistant tumors in mice enhanced the apoptotic response to chemotherapeutic agents and induced tumor regression (Wang et al., 1999a) . In contrast, others found that the stable inhibition of NFkB in dierent cancer cells did not increase their sensitivity to anti-neoplastic drugs (Bentires-Alj et al., 1999) . Another major obstacle to eective chemotherapy is the overexpression of the multi-drug resistance gene product (MDR) in many human malignancies. MDR proteins function as energy-dependent eux pumps that prevent intracellular cytotoxic drug accumulation. Interestingly, NF-kB has been implicated in the activation of mdr gene expression (Zhou and Kuo, 1997) . Thus, it is tempting to speculate that the suppression of NF-kB may enhance the intracellular accumulation of toxic drugs through inhibition of mdr gene expression. Although strategies to block NFkB activity in tumors may not be generally applicable, they oer a great potential to complement existing therapies.
Conclusions
Based on a variety of evidence, we can begin to recognize similarities in some of the functions needed for the induction of leukemias/lymphomas by the retroviral v-Rel oncoprotein, by transforming proteins of the human tumor viruses HTLV-1 and Epstein-Barr virus, and those conferred by alterations in Rel/NF-kB signaling in certain human cancers. A common consequence of rel/nfkb and ikb gene alterations in oncogenesis is likely to be the inappropriate activation of cellular gene expression. Similarly, mutations that inactivate the DNA-binding or transactivation functions of v-Rel abolish cell transformation (Gilmore, 1999, this issue) , and v-Rel has evolved mutations that increase its resistance to inhibition by IkBa (Sachdev and Hannink, 1998) . Moreover, mutations that abolish the abilities of the Tax protein of HTLV-1 (Sun and Ballard, 1999, this issue) or LMP1 or EBV (Cahir MacFarland et al., 1999, this issue) to activate NF-kB generally also inactivate their transforming functions. In non-viral human tumors, the functional inactivation of IkB factors through ikb gene mutations or enhanced IkB degradation can lead to chronic Rel/NF-kB activity. In addition, chromosomal aberrations that result in the ampli®cation and overexpression of cellular rel/nfkb genes are also likely to provide the necessary threshold of nuclear Rel/NF-kB activity for cell transformation. However, the transgenic expression of mammalian nfkb genes does not induce tumors (Gerondakis et al., 1999, this issue) . It is clear that more work is needed to understand the role of mammalian NF-kB factors in malignancy and the possible requirement for other cytogenetic alterations. The availability of methods to analyse mRNA expression patterns on a large scale also promises to bring signi®cant advances in the identi®cation of the critical target genes for Rel/NF-kB-mediated oncogenesis.
